Mr. Alejandro Antalich reports

BIOMIND LABS APPLAUDS LANDMARK EXECUTIVE ORDER ACCELERATING PSYCHEDELIC RESEARCH AND ACCESS IN THE UNITED STATES

Biomind Labs Inc. has welcomed the historic executive order signed by President Trump to accelerate research, regulatory pathways and patient access to psychedelic treatments.

This landmark policy shift marks a turning point in U.S. health care and drug policy, one that aligns directly with Biomind's long-term vision: to redefine how the world treats mental health and brain-related conditions.

A historic inflection point

The executive order directs federal agencies, including the Food and Drug Administration, to fast-track clinical development and review of psychedelic therapies, while expanding financing and support for research into compounds such as psilocybin, DMT, 5-MeO-DMT, MDMA and ibogaine. This initiative reflects growing recognition that psychedelic therapies may play a critical role in addressing the global mental health crisis, including conditions such as depression, anxiety, PTSD, addiction and neurodegenerative disorders.

From scientific breakthrough to regulatory momentum

This policy shift comes at a time when Biomind has already demonstrated unprecedented clinical outcomes, reinforcing the scientific foundation behind this new regulatory acceleration. In its previously announced phase 2 clinical trial of BMND08, a proprietary 5-MeO-DMT-based sublingual formulation for depression and anxiety in Alzheimer's disease, the company reported:

• 100-per-cent patient response rate;
• 100-per-cent remission from depression, anxiety and stress by week five;
• Statistically significant improvements across validated psychiatric scales;
• Evidence of cognitive enhancement, including improvements in executive function and processing speed.

These results position Biomind among the very few companies globally to demonstrate such a level of efficacy in a neurodegenerative population, historically one of the most challenging areas in drug development.

"What we are seeing today from a regulatory standpoint is the natural consequence of years of scientific validation," said Alejandro Antalich, chief executive officer of Biomind Labs. "At Biomind, we didn't wait for the system to change. We built the data that is now forcing the system to evolve."

Biomind at the centre of the paradigm shift

For years, Biomind has operated ahead of the curve, investing in clinical research, intellectual property and drug development platforms focused on psychedelic compounds and their derivatives. Today's announcement validates that strategy.

"This is not just regulatory progress, it is a paradigm shift," Mr. Antalich added. "We are witnessing the beginning of a new era in medicine, where mental health is treated with the same urgency, innovation and scientific rigour as any other major disease category."

Unlocking acceleration across the value chain

The executive order is expected to unlock multiple catalysts for the psychedelic biotech sector:

• Regulatory acceleration: fast-tracked Food and Drug Administration pathways could significantly shorten development timelines;
• Capital inflows: increased government support is likely to attract institutional and strategic investment;
• Clinical expansion: broader access to trials and patient populations;
• Destigmatization: federal endorsement reshapes public and medical perception.

For Biomind, this creates a powerful tailwind across its pipeline and strategic road map.

From vision to scalable impact

Biomind's platform, combining proprietary drug candidates, advanced delivery technologies and a global clinical network, is uniquely positioned to capitalize on this new regulatory environment. The company believes that psychedelic therapies will evolve from niche treatments into mainstream, first-line interventions for some of the most pressing health care challenges of its time.

"The future we envisioned, where psychedelic medicine is accessible, scalable and scientifically validated, is no longer theoretical," Mr. Antalich added. "It is now being actively built, and Biomind is already part of that future."

A global opportunity

While the executive order is United States-focused, its implications are global. Regulatory leadership from the United States is expected to influence policy frameworks worldwide, accelerating adoption across Europe, Latin America and emerging markets. Biomind intends to play a leading role in this transformation, bridging science, regulation and commercialization to bring breakthrough therapies to patients globally.

About Biomind Labs Inc.

Biomind Labs is a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs and proprietary nanotechnology-based delivery systems for psychiatric and neurological conditions that affect the central nervous system. Leveraging translational neuroscience and formulation science, Biomind aims to optimize the pharmacological profile of key endogenous and naturally derived molecules to address unmet needs in the CNS therapeutics. The company is committed to rigorous clinical validation and patient-centric innovation.

We seek Safe Harbor.